Abu Dhabi: Basel Ziyadeh, CEO of Gulf Pharmaceutical Industries (Julphar), has announced the company's plans to invest AED300 million over the next five years to enhance its manufacturing capabilities and expand its global reach. This strategic move aims to fortify Julphar's role as a significant contributor to the UAE's pharmaceutical sector.
According to Emirates News Agency, Ziyadeh disclosed the investment plan during the 'Make it in the Emirates 2025' event, highlighting the company's commitment to expanding its manufacturing base and localizing advanced technologies. Julphar's strategy involves collaborating with global partners to support the national economy by increasing non-oil pharmaceutical exports.
Ziyadeh further explained that in the past three years, the company has invested approximately AED100 million to improve its manufacturing infrastructure and integrate new technologies. During this period, Julphar has launched over 35 new pharmaceutical products, catering to the local market and international customers.
Reflecting on Julphar's history, Ziyadeh noted that the company, established over 45 years ago, was among the first UAE-based pharmaceutical firms to enter the global market. Today, Julphar exports more than 80% of its production to around 40 countries, leveraging one of the largest industrial bases in the Arab region.